CPNE3

Across TCGA pan-cancer cohorts, CPNE3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CPNE3 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CPNE3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CPNE3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where CPNE3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.810	0.701	.004	19	view →
CCRCC	OS	Tertile	All	0.778	0.962	.012	18	view →
LUAD	DFS	Median	All	0.818	0.979	.006	6	view →
LSCC	DFS	Median	II,III,IV	0.963	0.853	.021	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CPNE3–PDAC (DFS)

Open the PDAC breakdown →